IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR

Breast Cancer Research and Treatment

Volumn 130, Issue 2, 2011, Pages 465-475

  Roberti, M P ^a   Barrio, M M ^a   Bravo, A I ^b   Rocca, Y S ^a   Arriaga, J M ^a   Bianchini, M ^a   Mordoh, J ^a,c   Levy, E M ^a  

^a INSTITUTO ALEXANDER FLEMING   (Argentina)

^b Hospital Interzonal General de Agudos Eva Peronquot   (Argentina)

^c FUNDACIÓN INSTITUTO LELOIR   (Argentina)

Author keywords

Cetuximab mediated cytotoxicity; IL 2 and IL 15; K RAS status; Triple negative breast cancer

Indexed keywords

CD16 ANTIGEN; CETUXIMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 2; NATURAL KILLER CELL RECEPTOR NKG2D; RITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CODON; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA SEQUENCE; DRUG POTENTIATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NATURAL KILLER CELL; ONCOGENE K RAS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR IMMUNITY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; DNA MUTATIONAL ANALYSIS; FEMALE; GPI-LINKED PROTEINS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-15; INTERLEUKIN-2; KILLER CELLS, NATURAL; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; POINT MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, IGG; RECEPTORS, PROGESTERONE; UP-REGULATION;

EID: 82955165645     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1360-2     Document Type: Article

References (47)

1. Tavassoli F, Deville P (2003) World Health Organization: tumours of the breast and female genital organs (2003) (Who/IARC Classifications of Tumours). IARC, Lyon
2. Sorlie T (2004) Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 40:2667-2675 (Pubitemid 39574720)
3. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implica-tions. Proc Natl Acad Sci USA 98:10869-10874 (Pubitemid 32878711)
4. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recur-rence. Clin Cancer Res 13:4429-4434 (Pubitemid 47219710)
5. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L (2008) Response to neoadjuvant therapy and long-term survival in patients with tri-ple-negative breast cancer. J Clin Oncol 26:1275-1281
6. Ciardiello F, Tortora G (2008) e GFr antagonists in cancer treat-ment. N Eng J Med 358:1160-1174
7. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F (2009) Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 6:519-527
8. Van Cutsem E, Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal can-cer. N Engl J Med 360:1408-1417
9. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, Mc Allister PK, Morton RF, Schilsky RL (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with met-astatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091-2096
10. Fan Z, Masui H, Altas I, Mendelsohn J (1993) Blockade of epi-dermal growth factor receptor function by bivalent and mono-valent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 53:4322-4328 (Pubitemid 24146785)
11. Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K (2007) Antibody-dependent cellular cytotoxicity of Cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 98:1275-1280 (Pubitemid 46993549)
12. Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, Touge H, Makino H, Takata M, Miyata M, Nakamoto M, Burioka N, Shimizu E (2007) Antibody-dependent cellular cytotoxicity mediated by Cetuximab against lung cancer cell lines. Clin Cancer Res 13:1552-1561 (Pubitemid 46450447)
13. Roda JM, Joshi T, Butchar JP, Mc Alees JW, Lehman A, Trid-andapani S, Carson WE 3rd (2007) The activation of natural killer cell effector functions by Cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 13:6419-6428 (Pubitemid 350075032)
14. Dechant M, Weisner W, Berger S, Peipp M, Beyer T, Schneider-Merck T, Lammerts van Bueren JJ, Bleeker WK, Parren PW, van de Winkel JG, Valerius T (2008) Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 68:4998-5003
15. Levy EM, Sycz G, Arriaga JM, Barrio MM, von Euw EM, Mor-ales SB, González M, Mordoh J, Bianchini M (2009) Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells. Innate Immun 15:91-100
16. Correale P, Marra M, Remondo C, Migali C, Misso G, Arcuri FP, Del Vecchio MT, Carducci A, Loiacono L, Tassone P, Ab-bruzzese A, Tagliaferri P, Caraglia M (2010) Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-tar-geted antibody-dependent cell-mediated-cytotoxicity (ADCC). Eur J Cancer 9:1703-1711
17. Leibson PJ (1997) Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity 6:655-661 (Pubitemid 27305728)
18. Terunuma H, Deng X, Dewan Z, Fujimoto S, Yamamoto N (2008) Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections. Int Rev Immunol 27:93-110 (Pubitemid 351589824)
19. Anfossi N, André P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton D, Romagné F, Ug-olini S, Vivier E (2006) Human NK cell education by inhibitory receptors for MHC class I. Immunity 25:331-342 (Pubitemid 44224147)
20. Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J (2009) In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 27:5944-5951
21. Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, Ratto GB, Mingari MC, Moretta L, Ferlazzo G (2008) Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer 112:863-875 (Pubitemid 351240580)
22. Wulff S, Pries R, Börngen K, Trenkle T, Wollenberg B (2009) Decreased levels of circulating regulatory NK cells in patients with head and neck cancer throughout all tumor stages. Anti-cancer Res 29:3053-3057
23. Watanabe M, Kono K, Kawaguchi Y, Mizukami Y, Mimura K, Maruyama T, Fujii H (2010) Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma. Br J Cancer 102:520-529
24. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, Eldridge P, Leung WH, Campana D (2009) Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 69:4010-4017
25. Bryceson YT, March ME, Ljunggren HG, Long EO (2006) Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107:159-166 (Pubitemid 43053538)
26. Oberlies J, Watzl C, Giese T, Luckner C, Kropf P, Müller I, Ho AD, Munder M (2009) Regulation of NK cell function by human granulocyte arginase. J Immunol 182:5259-5267
27. Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, Croce CM, Baumann H, Caligiuri MA (1997) A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 99:937-943 (Pubitemid 27123630)
28. Cooper MA, Bush JE, Fehniger TA, Van Deusen JB, Waite RE, Liu Y, Aguila HL, Caligiuri MA (2002) In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 100:3633-3638 (Pubitemid 35303933)
29. Boyiadzis M, Memon S, Carson J, Allen K, Szczepanski MJ, Vance BA, Dean R, Bishop MR, Gress RE, Hakim FT (2008) Upregulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 lev-els. Biol Blood Marrow Transplant 14:290-300 (Pubitemid 351218196)
30. Corkery B, Crown J, Clynes M, O'Donovan N (2009) Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 20:862-867
31. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massagué J (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459:1005-1009
32. Gholam D, Chebib A, Hauteville D, Bralet MP, Jasmin C (2007) Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer. Anticancer Drugs 18:835-837 (Pubitemid 46975972)
33. Bover L, Barrio M, Slavutsky I, Bravo AI, Quintans C, Bagnǎti A, Lema B, Schiaffi J, Yomha R, Mordoh J (1991) Description of a new human breast cancer cell line, IIB-BR-G, established from a primary undifferentiated tumor. Breast Cancer Res Treat 19:47-56
34. Bover L, Barrio M, Bravo AI, Slavutsky I, Larripa I, Bolondi A, Ayala M, Mordoh J(1998) The human breast cancer cell line IIB-BR-G has amplified c-myc and c-fos oncogenes in vitro and is spontaneously metastatic in vivo. Cell Mol Biol (Noisy-le-grand) 44:493-504
35. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P (2006) KRAS mutation status is pre-dictive of response to cetuximab therapy in colorectal cancer. Clin Cancer Res 66:3992-3995
36. Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Jänne PA (2005) Differential effects of gefitinib and cetuximab on non-smallcell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 97:1185-1194 (Pubitemid 41258224)
37. Luo FR, Yang Z, Dong H, Camuso A, Mc Glinchey K, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, Rose WC, Kramer RA, Wild R, Lee FY (2005) Correlation ofpharmacokinetics with the antitumor activity of cetuximab in nude mice bearing the GEOhuman colon carcinoma xenograft. Cancer Chem other Pharmacol 56:455-464 (Pubitemid 41549146)
38. Khan KD, Emmanouilides C, Benson DM Jr, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis CF, Banks AL, Chen L, Byrd JC, Caligiuri MA (2006) A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin Cancer Res 12:7046-7053 (Pubitemid 44974502)
39. Alpaugh RK, von Mehren M, Palazzo I, Atkins MB, Sparano JA, Schuchter L, Weiner LM, Dutcher JP (1998) Phase Ib trial for malignant melanoma using R24 monoclonal antibody, interleu-kin-2/α-interferon. Med Oncol 15:191-198 (Pubitemid 28496887)
40. Golay J, Manganini M, Facchinetti V, Gramigna R, Broady R, Borleri G, Rambaldi A, Introna M (2003) Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 88:1002-1012 (Pubitemid 37151151)
41. Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, Baselga J, Caligiuri MA (2001) Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 31:3016-3025 (Pubitemid 32994553)
42. Budagian V, Bulanova E, Paus R, Bulfone-Paus S (2006) IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev 17:259-280 (Pubitemid 44038618)
43. Waldmann TA, Dubois S, Tagaya Y (2001) Contrasting roles of IL-2 and IL-15 in the life and death oflymphocytes: implications forimmunotherapy. Immunity 14:105-110 (Pubitemid 32206513)
44. Becknell B, Caligiuri MA (2005) Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 86:209-239 (Pubitemid 40215694)
45. Ranson T, Vosshenrich CA, Corcuff E, Richard O, Muller W, Di Santo JP (2003) IL-15 is an essential mediator ofperipheral NK-cell homeostasis. Blood 101:4887-4893 (Pubitemid 36857750)
46. Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, Croce CM, Baumann H, Caligiuri MA (1997) A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 99:937-943 (Pubitemid 27123630)
47. Chin YE, Kitagawa M, Kuida K, Flavell RA, Fu XY (1997) Activation of the STAT signaling pathway can cause expression of caspase 1and apoptosis. Mol Cell Biol 17:5328-5337 (Pubitemid 27357631)